ReviewBrain and behavior2022
COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2.
Review in Brain and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- New-Onset Myasthenia Gravis Associated with SARS-CoV-2 Infection: A Systematic Review.Life (Basel, Switzerland) · 2026Review
- Double-seropositive Myasthenia Gravis Following COVID-19.Internal medicine (Tokyo, Japan) · 2025Article
- The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study.Virology journal · 2025Article
- COVID-19-associated delayed-onset MuSK-positive myasthenia gravis presenting solely with respiratory failure: a case report.Frontiers in immunology · 2025Article
- Pyridostigmine improves hand grip strength in patients with myalgic encephalomyelitis/chronic fatigue syndrome.Frontiers in neuroscience · 2025Article
- The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis.Vaccines · 2024Article
- Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis/mechanisms of long COVID.Medical review (2021) · 2024Review
- Seronegative Myasthenia Gravis: A Rare Disease Triggered by SARS-CoV-2 or a Coincidence?Cureus · 2024Article
- Myasthenia Gravis Triggered by a COVID-19 Infection: A Case Report and Literature Review.Cureus · 2024Article
- Is COVID-19 Infection a Multiorganic Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2.Journal of clinical medicine · 2024Review
- Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.Frontiers in public health · 2024Article
- Association between COVID-19 and myasthenia gravis (MG): A genetic correlation and Mendelian randomization study.Brain and behavior · 2023Article
- Neuro-ophthalmic sequelae post-COVID-19.Indian journal of ophthalmology · 2023Article
- COVID-19: a modern trigger for Guillain-Barre syndrome, myasthenia gravis, and small fiber neuropathy.Frontiers in neuroscience · 2023Review
- Clinical Characteristics of Myasthenia Gravis Patients with COVID-19 in Guangxi, China: A Case-Control Study.Journal of inflammation research · 2023Article
- COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2.Brain and behavior · 2022Review
- Molecular and Cellular Mechanisms Underlying Neurological and Neuropsychological Manifestations of COVID-19.Innovations in clinical neuroscienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis review highlights the potential mechanisms of neuromuscular manifestation of COVID-19, especially myasthenia gravis (MG).
methodsAn extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020.
resultsExacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID-19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders.
conclusionsFurther clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.